Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Active Biotech AB's Enterprise Value is €5.96 Mil.
Active Biotech AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-2.88 Mil. Therefore, Active Biotech AB's EV-to-OCF for today is -2.07.
The historical rank and industry rank for Active Biotech AB's EV-to-OCF or its related term are showing as below:
FRA:BTP'
s EV-to-OCF Range Over the Past 10 Years
Min: -25.9 Med: -5.73 Max: 1.16
Current: -2.1
During the past 13 years, the highest EV-to-OCF of Active Biotech AB was 1.16. The lowest was -25.90. And the median was -5.73.
FRA:BTP's EV-to-OCF is ranked worse than 58.89% of 1406
companies
in the Biotechnology industry
Industry Median: -3.7
vs FRA:BTP: -2.10
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Active Biotech AB's PE Ratio (TTM) for today is calculated as:
Active Biotech AB's share price for today is €0.4085.
Active Biotech AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.127.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Active Biotech AB EV-to-OCF Related Terms
Active Biotech AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Active Biotech AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Active Biotech AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Active Biotech AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Active Biotech AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Active Biotech AB's EV-to-OCF falls into.
Active Biotech AB's current Enterprise Value is €5.96 Mil.
Active Biotech AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Active Biotech AB (FRA:BTP) has a EV-to-OCF of -2.07 as of Sep. 07, 2026. According to the industry distribution chart, Active Biotech AB ranks #828 out of 1406 companies in the Biotechnology industry, placing it in the top 58.9%.
Is Active Biotech AB's EV-to-OCF too high?
Active Biotech AB's current EV-to-OCF is -2.07. Based on the distribution chart, Active Biotech AB ranks #828 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Active Biotech AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Active Biotech AB ranks #828 out of 1406 companies for EV-to-OCF. This places Active Biotech AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Active Biotech AB's current EV-to-OCF is -2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Based on GuruFocus' analysis, Active Biotech AB (FRA:BTP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.41 — trading 214.2% above its estimated fair value. The current EV-to-OCF is -2.07. Active Biotech AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Active Biotech AB (FRA:BTP), the current EV-to-OCF is -2.07 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Active Biotech AB (FRA:BTP) Overvalued in 2026?
Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued.
The current stock price of €0.41 is trading 214.2% above its estimated GF Value™ of €0.13.
GuruFocus considers Active Biotech AB to be Significantly Overvalued.
Key valuation signals for FRA:BTP:
EV-to-OCF: -2.07
GF Value™: €0.13 vs. price of €0.41 (214.2% above fair value)
No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
30GF Score
Get the complete analysis for FRA:BTP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BTP has been successfully added to your 
